Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?
Kuo
Alexander
A
Terrault
Norah A
NA
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D023381:Endpoint Determination; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality / Q000517:prevention & control; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence; D015996:Survival Rate; D014180:Transplantation; D014779:Virus Replication / Q000187:drug effects / Q000502:physiology
D000998:Antiviral Agents